Pharmaceutical News

RSS

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.

24 Jun 2010

Treatment options for patients with MS

The best one-word description for multiple sclerosis is "unpredictable," according to the June issue of Mayo Clinic Women's HealthSource. MS interferes with the communication between the brain and the rest of the body. Just how that interference plays out in symptoms is different for everyone -- thus, the unpredictable label.

24 Jun 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

EUCODIS Bioscience launches high-performance beta-lactamase

EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.

23 Jun 2010

US physicians concerned about health risk to patients from heat-damaged medicinal products

In a recent Harris Interactive survey of US physicians about the proper storage and handling of temperature-sensitive medicines prescribed and administered to patients, physicians reported being concerned about this issue, and the overwhelming majority are concerned that heat-damaged products resulting from cumulative exposure to temperatures outside the specified temperature range pose a health risk to patients. The announcement of the study findings was made today by Temptime Corporation.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Global weight management ingredients market to reach $13.9 million by 2015

Obesity rates, which have been steadily rising in Europe and the United States, are now increasing in Asian nations as well. While healthy eating and lifestyle management are the key solutions to weight management, they remain challenging for many consumers. As a result, the weight management ingredients market offers significant prospects worldwide.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

PBMs: Post Office plan to end Saturday shipments could boost drug prices

Pharmacy-benefits management companies, including CVS Caremark and Medco, are worried that a U.S. Postal Service plan to end Saturday delivery could raise mail-order drug prices, Bloomberg Businessweek reports. "The pharmacy-benefits management companies, which shipped more than 150 million drug orders last year, joined retailer Crate and Barrel and publishers of small newspapers to challenge the Postal Service and its plan to cut service to save about $3 billion a year." The Post Office is trying to combat a projected $7 billion deficit this year (Keane, 6/21).

23 Jun 2010

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

GlaxoSmithKline and Medivir today announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets. Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Walmart and Eli Lilly and Company announced today they're teaming up to provide an affordable insulin option for people with diabetes.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

Pharmaceutical News

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Treatment options for patients with MS

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

EUCODIS Bioscience launches high-performance beta-lactamase

US physicians concerned about health risk to patients from heat-damaged medicinal products

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Global weight management ingredients market to reach $13.9 million by 2015

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

PBMs: Post Office plan to end Saturday shipments could boost drug prices

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

European drugmakers lead in making medicines available to developing world, Index says

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

TheraQuest launches new analgesic product pipeline

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

Exercise alone without creatine supplements helps in cardiac rehabilitation

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News